Tartu, Estonia, home to SNP array maker Asper Biotech, is a long, long way from Silicon Valley. But Asper has not given up on its California style high-tech dream of success with its array-based SNP genotyping system.
“We are looking at a low cost, high-throughput platform,” said Asper co-founder and chief scientific officer Andres Metspalu. “Our glass slides and 50,000 SNPs would be the ideal mix. In this we can beat anybody.”